CA3156452A1 - Npy2 receptor agonists - Google Patents

Npy2 receptor agonists

Info

Publication number
CA3156452A1
CA3156452A1 CA3156452A CA3156452A CA3156452A1 CA 3156452 A1 CA3156452 A1 CA 3156452A1 CA 3156452 A CA3156452 A CA 3156452A CA 3156452 A CA3156452 A CA 3156452A CA 3156452 A1 CA3156452 A1 CA 3156452A1
Authority
CA
Canada
Prior art keywords
receptor agonists
analogs
npy2 receptor
npy2
pyy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3156452A
Other languages
English (en)
French (fr)
Inventor
Peter Wilhelm Haebel
Albert Brennauer
Charlotte Stahl MADSEN
Soren Ljungberg Pedersen
Stefan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA3156452A1 publication Critical patent/CA3156452A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3156452A 2019-11-11 2020-11-09 Npy2 receptor agonists Pending CA3156452A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
EP19208394.7 2019-11-11
PCT/EP2020/081513 WO2021094259A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Publications (1)

Publication Number Publication Date
CA3156452A1 true CA3156452A1 (en) 2021-05-20

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3156452A Pending CA3156452A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Country Status (20)

Country Link
US (3) US20210139548A1 (OSRAM)
EP (1) EP4058047A1 (OSRAM)
JP (1) JP2023500895A (OSRAM)
KR (1) KR20220100925A (OSRAM)
CN (1) CN114641303A (OSRAM)
AR (1) AR120440A1 (OSRAM)
AU (1) AU2020384729A1 (OSRAM)
CA (1) CA3156452A1 (OSRAM)
CL (1) CL2022001227A1 (OSRAM)
CO (1) CO2022006046A2 (OSRAM)
CR (1) CR20220206A (OSRAM)
DO (1) DOP2022000097A (OSRAM)
EC (1) ECSP22037660A (OSRAM)
IL (1) IL292601A (OSRAM)
JO (1) JOP20220110A1 (OSRAM)
MX (1) MX2022005661A (OSRAM)
PE (1) PE20221168A1 (OSRAM)
PH (1) PH12022551101A1 (OSRAM)
TW (1) TWI864155B (OSRAM)
WO (1) WO2021094259A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂
PE20231566A1 (es) * 2020-08-07 2023-10-04 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
CN119677527A (zh) 2022-08-18 2025-03-21 勃林格殷格翰国际有限公司 包含长效glp-1/胰高血糖素及npy2受体激动剂的组合疗法
US20240247080A1 (en) * 2022-12-21 2024-07-25 Boehringer Ingelheim International Gmbh Glp1/gip/npy2 receptor triple agonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
SG158141A1 (en) 2004-12-13 2010-01-29 Amylin Pharmaceuticals Inc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP1962959B1 (en) 2005-12-07 2012-03-14 F. Hoffmann-La Roche AG Neuropeptide-2 receptor-agonists
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
CN101939022A (zh) 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
PL2370460T3 (pl) 2008-12-15 2014-09-30 Zealand Pharma As Analogi glukagonu
BRPI0823377A2 (pt) 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
MX2012000564A (es) 2009-07-13 2012-04-11 Zealand Pharma As Analogos de glucagon acilados.
WO2011033068A1 (en) 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
JP2013510829A (ja) * 2009-11-13 2013-03-28 ノヴォ ノルディスク アー／エス 長時間作用型ｙ２受容体アゴニスト
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
EA201291234A1 (ru) 2010-06-24 2013-07-30 Зилэнд Фарма А/С Аналоги глюкагона
RU2669999C2 (ru) 2011-06-10 2018-10-17 Ново Нордиск А/С Полипептиды
US20130316941A1 (en) 2011-12-23 2013-11-28 Boehringer Ingelheim International Gmbh Glucagon analogues
MX356641B (es) 2012-05-03 2018-06-07 Zealand Pharma As Compuestos agonistas dobles de gip-glp-1 y procedimientos.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
JP2016519130A (ja) 2013-05-02 2016-06-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 治療ペプチド
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
SI3321278T1 (sl) 2013-11-14 2019-04-30 Keybioscience Ag Mimetiki kalcitonina za zdravljenje bolezni in motenj
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
JP6629198B2 (ja) * 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
RU2726777C2 (ru) * 2015-06-12 2020-07-15 Ново Нордиск А/С Селективные соединения пептида yy и их применения
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
PL3398961T3 (pl) 2015-12-31 2022-09-26 Hanmi Pharm. Co., Ltd. Potrójny aktywator aktywujący receptory glukagonu, glp-1 i gip
EP3452088A4 (en) 2016-05-03 2020-04-15 The Scripps Research Institute TRKB AGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
CN108289005B (zh) 2017-01-09 2021-06-29 中兴通讯股份有限公司 信令发送、接收方法及装置
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
TWI865836B (zh) * 2018-11-01 2024-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂

Also Published As

Publication number Publication date
AR120440A1 (es) 2022-02-16
PH12022551101A1 (en) 2023-11-13
US20210139548A1 (en) 2021-05-13
US12054525B2 (en) 2024-08-06
EP4058047A1 (en) 2022-09-21
KR20220100925A (ko) 2022-07-18
JP2023500895A (ja) 2023-01-11
CL2022001227A1 (es) 2023-02-03
MX2022005661A (es) 2022-09-07
CO2022006046A2 (es) 2022-05-20
TW202134263A (zh) 2021-09-16
WO2021094259A1 (en) 2021-05-20
AU2020384729A1 (en) 2022-04-14
CR20220206A (es) 2022-06-16
CN114641303A (zh) 2022-06-17
US20230340039A1 (en) 2023-10-26
US20250002544A1 (en) 2025-01-02
JOP20220110A1 (ar) 2023-01-30
DOP2022000097A (es) 2022-06-15
ECSP22037660A (es) 2022-06-30
TWI864155B (zh) 2024-12-01
PE20221168A1 (es) 2022-07-25
IL292601A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
CA3156452A1 (en) Npy2 receptor agonists
CR20230074A (es) Agonistas del receptor npy2 solubles
MA42561A (fr) Procédés de formulation de compositions de conjugués anticorps-médicament
SA521421873B1 (ar) نظائر بروتين تيروسين-تيروسين وطرق لاستخدامها
NZ784645A (en) Relaxin analogs and methods of using the same
MX2011011772A (es) Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
PH12018502465A1 (en) Mic-1 compounds and use thereof
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PH12019550241A1 (en) Mic-1 compounds and uses thereof
EP4595950A3 (en) Annexin a1 n-terminal peptide formulations and methods
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
ZA202203563B (en) Pediatric suspension formulation
ZA202200331B (en) Naltrexone formulation
MX2022004014A (es) Composicion liofilizada que contiene 2-((s)-2-acetamido-3-(1h-indo l-3-il)propanamido)-6-diazo-5-oxohexanoato de (s)-isopropilo para administracion intravenosa y su uso.
EA202192475A1 (ru) Способ получения стабильных пептидных составов
BR112022006297A2 (pt) Agonistas de receptor de npy2
MA49754B1 (fr) Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
MA52290B1 (fr) Préparations de médicaments d'hormone thyroïdienne de poudre sèche pour administration à inhaler
EA202190923A1 (ru) Аналоги белка тирозин-тирозин и способы их применения
PH12022551041A1 (en) Crizanlizumab containing antibody formulation
MX2020012486A (es) Composicion de inmunoglobulinas humanas concentradas.